Tivic Health names new transfer and warrant agent

Tivic Health Systems, Inc. has appointed Odyssey Transfer and Trust Company as its new transfer agent and registrar, effective as of August 30, 2025.

Rhea-AI Filing Summary

Tivic Health Systems, Inc. has appointed Odyssey Transfer and Trust Company as its new transfer agent and registrar, effective as of August 30, 2025. All registered shares of common stock and related records will move from the prior transfer agent, Equiniti Trust Company, LLC, to Odyssey by that date. As of the same effective date, Odyssey will also replace Equiniti as successor warrant agent under the May 13, 2024 Warrant Agency Agreement covering the Company’s Series B Warrants issued to certain investors.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Tivic Health Systems (TIVC) announce in this 8-K?

The company disclosed that effective August 30, 2025, it has appointed Odyssey Transfer and Trust Company as its new transfer agent and registrar, replacing Equiniti Trust Company, LLC, and that Odyssey will also become successor warrant agent for its Series B Warrants.

When does Odyssey become Tivic Health Systems’ new transfer agent?

Odyssey Transfer and Trust Company will serve as Tivic Health Systems’ new transfer agent and registrar effective as of August 30, 2025, which is referred to as the Effective Date.

Which firm is Odyssey replacing for Tivic Health Systems (TIVC)?

Odyssey is replacing Equiniti Trust Company, LLC as Tivic Health Systems’ transfer agent and registrar, and will also replace Equiniti as successor warrant agent under the May 13, 2024 Warrant Agency Agreement.

What happens to Tivic Health Systems’ share records under this change?

All of Tivic Health Systems’ registered shares of common stock and related records will be transferred from Equiniti Trust Company, LLC to Odyssey Transfer and Trust Company on or before August 30, 2025.

Which Tivic Health Systems warrants are affected by the new warrant agent?

The change applies to the Series B Warrants that were sold and issued by Tivic Health Systems to certain investors on May 13, 2024, with Odyssey becoming the successor warrant agent under the existing Warrant Agency Agreement.

Does this Tivic Health (TIVC) 8-K involve any new securities issuance?

The disclosure describes an administrative change in transfer and warrant agents for existing common stock and Series B Warrants; it does not describe any new securities issuance.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/27/2025 - 04:12 PM Learn about SEC filing dates

false000178774000017877402025-08-272025-08-27

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 27, 2025

Tivic Health Systems, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-41052	81-4016391
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
47685 Lakeview Blvd.
Fremont, California				94538
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: 888 276-6888

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		TIVC		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

Effective as of August 30, 2025 (the “Effective Date”), Tivic Health Systems, Inc. (the “Company”) has appointed Odyssey Transfer and Trust Company (“Odyssey”) to serve as its new transfer agent and registrar. All of the Company’s registered shares of common stock and related records will be transferred from Equiniti Trust Company, LLC (“Equiniti”), the Company’s prior transfer agent and registrar, to Odyssey on or before the Effective Date.

Additionally, effective as of the Effective Date, Odyssey will replace Equiniti as the successor warrant agent, pursuant to that Warrant Agency Agreement originally entered into by and between the Company and Equiniti on May 13, 2024, for those Series B Warrants sold and issued by the Company to certain investors on May 13, 2024.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			TIVIC HEALTH SYSTEMS, INC.
Date:	August 27, 2025	By:	/s/ Jennifer Ernst
			Name: Jennifer Ernst Title: Chief Executive Officer